|
Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) DCF -Bewertung
CN | Healthcare | Drug Manufacturers - Specialty & Generic | SHH
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) Bundle
Bewerten Sie die finanziellen Aussichten von Shanghai Shyndec Pharmaceutical Co., Ltd. wie ein Experte! Dieser (600420SS) DCF-Taschenrechner bietet Ihnen vorgefüllte Finanzdaten und vollständige Flexibilität, um das Umsatzwachstum, WACC, Margen und andere wesentliche Annahmen zu ändern, um sich an Ihren Prognosen anzupassen.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12,199.1 | 12,556.3 | 13,944.9 | 12,959.3 | 11,931.8 | 11,901.7 | 11,871.7 | 11,841.7 | 11,811.8 | 11,782.0 |
| Revenue Growth, % | 0 | 2.93 | 11.06 | -7.07 | -7.93 | -0.25233 | -0.25233 | -0.25233 | -0.25233 | -0.25233 |
| EBITDA | 1,984.7 | 1,891.1 | 1,848.9 | 1,939.3 | 1,978.2 | 1,812.2 | 1,807.6 | 1,803.1 | 1,798.5 | 1,794.0 |
| EBITDA, % | 16.27 | 15.06 | 13.26 | 14.96 | 16.58 | 15.23 | 15.23 | 15.23 | 15.23 | 15.23 |
| Depreciation | 730.9 | 736.7 | 824.2 | 848.5 | 825.2 | 743.4 | 741.6 | 739.7 | 737.8 | 736.0 |
| Depreciation, % | 5.99 | 5.87 | 5.91 | 6.55 | 6.92 | 6.25 | 6.25 | 6.25 | 6.25 | 6.25 |
| EBIT | 1,253.8 | 1,154.4 | 1,024.7 | 1,090.7 | 1,152.9 | 1,068.8 | 1,066.1 | 1,063.4 | 1,060.7 | 1,058.0 |
| EBIT, % | 10.28 | 9.19 | 7.35 | 8.42 | 9.66 | 8.98 | 8.98 | 8.98 | 8.98 | 8.98 |
| Total Cash | 5,164.1 | 3,719.5 | 4,284.2 | 6,148.2 | 5,972.6 | 4,764.9 | 4,752.8 | 4,740.8 | 4,728.9 | 4,717.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1,763.6 | 2,602.3 | 3,047.5 | 2,655.6 | 2,050.8 | 2,254.5 | 2,248.8 | 2,243.2 | 2,237.5 | 2,231.9 |
| Account Receivables, % | 14.46 | 20.72 | 21.85 | 20.49 | 17.19 | 18.94 | 18.94 | 18.94 | 18.94 | 18.94 |
| Inventories | 2,318.4 | 3,281.2 | 3,072.4 | 2,439.8 | 2,280.4 | 2,501.9 | 2,495.6 | 2,489.3 | 2,483.0 | 2,476.7 |
| Inventories, % | 19 | 26.13 | 22.03 | 18.83 | 19.11 | 21.02 | 21.02 | 21.02 | 21.02 | 21.02 |
| Accounts Payable | 1,368.8 | 2,104.5 | 1,542.3 | 1,421.6 | 1,558.6 | 1,501.4 | 1,497.6 | 1,493.8 | 1,490.0 | 1,486.3 |
| Accounts Payable, % | 11.22 | 16.76 | 11.06 | 10.97 | 13.06 | 12.61 | 12.61 | 12.61 | 12.61 | 12.61 |
| Capital Expenditure | -403.8 | -378.0 | -521.4 | -307.4 | -357.2 | -367.2 | -366.3 | -365.3 | -364.4 | -363.5 |
| Capital Expenditure, % | -3.31 | -3.01 | -3.74 | -2.37 | -2.99 | -3.09 | -3.09 | -3.09 | -3.09 | -3.09 |
| Tax Rate, % | 36.9 | 36.9 | 36.9 | 36.9 | 36.9 | 36.9 | 36.9 | 36.9 | 36.9 | 36.9 |
| EBITAT | 1,085.1 | 997.9 | 916.4 | 961.4 | 727.4 | 884.2 | 882.0 | 879.8 | 877.5 | 875.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -1,301.1 | 290.9 | 420.5 | 2,406.4 | 2,096.7 | 778.0 | 1,265.5 | 1,262.3 | 1,259.1 | 1,255.9 |
| WACC, % | 5.13 | 5.13 | 5.14 | 5.13 | 5.03 | 5.11 | 5.11 | 5.11 | 5.11 | 5.11 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 4,982.9 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 1,300 | |||||||||
| Terminal Value | 80,680 | |||||||||
| Present Terminal Value | 62,881 | |||||||||
| Enterprise Value | 67,864 | |||||||||
| Net Debt | -4,839 | |||||||||
| Equity Value | 72,703 | |||||||||
| Diluted Shares Outstanding, MM | 1,273 | |||||||||
| Equity Value Per Share | 57.09 |
What You Will Receive
- Authentic Shanghai Shyndec Data: Comprehensive financials – covering everything from revenue to EBIT – based on real and projected metrics.
- Complete Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates to fit your analysis.
- Instant Valuation Refresher: Automatic updates to reassess how changes affect the fair value of Shanghai Shyndec Pharmaceutical (600420SS).
- Flexible Excel Template: Designed for swift modifications, scenario analysis, and in-depth forecasting.
- Efficient and Precise: Eliminate the need to create models from the ground up while ensuring accuracy and adaptability.
Key Features
- Pre-Loaded Data: Shanghai Shyndec Pharmaceutical Co., Ltd.’s historical financial statements and pre-filled forecasts.
- Fully Adjustable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins to suit your analysis.
- Instant Results: View the intrinsic value of Shanghai Shyndec Pharmaceutical Co., Ltd. recalculated in real time.
- Clear Visual Outputs: Dashboard charts illustrate valuation results and significant metrics.
- Built for Accuracy: A professional tool tailored for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review the pre-filled data for Shanghai Shyndec Pharmaceutical Co., Ltd. (600420SS), including historical and projected figures.
- Step 3: Modify the key assumptions (highlighted in yellow) according to your analysis.
- Step 4: Observe the automatic updates reflecting the intrinsic value of Shanghai Shyndec Pharmaceutical Co., Ltd. (600420SS).
- Step 5: Utilize the results for making investment decisions or preparing reports.
Why Opt for This Calculator?
- All-in-One Solution: Features DCF, WACC, and financial ratio analyses all integrated into a single tool.
- Flexible Inputs: Modify the yellow-highlighted fields to explore different financial scenarios.
- In-Depth Analysis: Automatically computes the intrinsic value and Net Present Value for Shanghai Shyndec Pharmaceutical Co., Ltd. (600420SS).
- Preloaded Information: Comes with historical and projected data for precise initial calculations.
- High-Quality Standards: Perfect for financial analysts, investors, and business advisors.
Who Can Benefit from This Product?
- Investors: Make informed choices with a comprehensive valuation tool tailored for [Symbol] (600420SS).
- Financial Analysts: Enhance efficiency with a customizable DCF model pre-designed for [Symbol] (600420SS).
- Consultants: Seamlessly modify the template for client reports or presentations centered on [Symbol] (600420SS).
- Finance Enthusiasts: Expand your knowledge of valuation practices with practical examples related to [Symbol] (600420SS).
- Educators and Students: Utilize this as a hands-on learning resource in finance courses focusing on [Symbol] (600420SS).
Overview of Template Components
- Historical Data: Features Shanghai Shyndec Pharmaceutical's previous financial performance and foundational forecasts.
- DCF and Levered DCF Models: Comprehensive templates to determine the intrinsic value of Shanghai Shyndec Pharmaceutical (600420SS).
- WACC Sheet: Pre-calculated metrics for the Weighted Average Cost of Capital.
- Editable Inputs: Adjust key factors such as growth rates, EBITDA percentages, and CAPEX estimates.
- Quarterly and Annual Statements: An extensive overview of Shanghai Shyndec Pharmaceutical's financial data.
- Interactive Dashboard: Dynamically visualize valuation outcomes and future projections.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.